Jazz Pharmaceuticals plc (JAZZ) is in Healthcare, Biotechnology, based in Ireland, listed on NasdaqGS. Market cap 14.44B USD. 52-week range 128.80 to 266.38 USD. Trailing P/E 15.2. Data as of 2026-10-09.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to ...